OM-X Capsule safety research

Posted On: August 4, 2020
Categories:Press Release,


Dr. Ohhira’s® Probiotic Supplement Information

Our unique probiotic products with all-natural ingredients support a healthy gut. A test conducted by Essential Formulas Incorporated and BioBank Ltd. (Japan) investigated the effects of our Dr. Ohhira’s Probiotics in a focused study. Here’s a summary of information gleaned from the study published in the October 2013 issue of the Integrative Medicine (IMJC), Vol. 12, No 5.

Why Probiotics?

Uncomfortable gastrointestinal symptoms such as indigestion, bloating, constipation and diarrhea can be common in otherwise healthy individuals. Many researchers believe that increasing the intake of probiotics can help reduce these GI conditions. 

A healthy person’s digestive tract contains trillions of beneficial bacteria from more than 400 different species. Probiotic bacteria help promote healthy bowel function and control harmful bacteria in the gut which alleviates many GI troubles. These friendlybacteria are found in fermented foods like yogurt, miso and even sauerkraut. Instead of eating them in food, quality supplements can help to provide probiotics for better intestinal health.

A study of safety and tolerability of Dr. Ohhira’s Probiotic capsules

Researchers in the study recruited 51 healthy men and women through a clinical research center. Participants were between 18 and 60 years old, had not previously used Dr Ohhira’s capsule, and had no history of significant illness. None of the participants were taking prescription medication, with the exception of birth control pills.

The 50 participants in the double-blind study were randomized, with half getting a Dr. Ohhira’s Probiotics pill and the other half taking a placebo. The test lasted thirty days, with baseline, mid-study and post-study health evaluations. 

Conclusions of the study

Of the original 51 participants, 46 completed all of the laboratory and other assessments. Twenty-four of these were in the active group and twenty-two in the placebo group. Researchers judged compliance by pill counts, concluding that that participants took more than 90% of their required doses. This average was mostly dragged down by one participant in the active group who only managed to take 65% of the prescribed dose. 

Researchers analyzed the effects of the Dr. Ohhira’s Probiotics product and the placebo on the 46 participants. Of these, 25 were male, 21 were female. Twenty-five identified as white, thirteen as black and three as Asian. Five participants were of unknown ethnicity. The mean age in the active group was 37. In the placebo group, the mean age was 41.

Both the active and placebo groups reported mild adverse effects. In the active group, 46% of participants reported some degree of nausea, bloating, increased appetite and/or flatus. Fifty percent of the control group reported some combination of nausea, diarrhea, abdominal pain, flatus and/or constipation. The investigator judged these symptoms to be insignificant and probably unrelated to the product being tested, as they presented almost equally in the control and active groups.

Some champions of Dr Ohhira’s probiotics, vitamins and other unique types of product weren’t surprised that the study showed Dr. Ohhira’s Probiotics capsules to be safe and well-tolerated. 

“The scientific outcome of this study was no surprise, as I have been recommending Dr. Ohhira’s Probiotics to my patients for years with exceptional clinical results,” said Fred Pescatore, MD, co-author of the study.

“Nearly thirty years of supporting science has earned Dr. Ohhira’s Probiotics® the respect of the scientific, academic and medical, and holistic health communities,” said Michael Schoor, Chairman of the Board of Directors of Essential Formulas Incorporated. “This study serves as an added component in validating their trust in this exceptional supplement is merited!”

All rights reserved


Egilius L. H. Spierings, MD, PhD, is the director of research at MedVadis Research Corporation in Watertown, Massachusetts and Harvard Medical School in Boston, Massachusetts. Thomas Walshe, MD, is chief of the Division of General Neurology at Brigham and Women’s Hospital, an affiliate of Harvard Medical School. Fred Pescatore, MD, is the medical director of Medicine 369 in New York, New York.